SK Bioscience develops vaccines using advanced manufacturing techniques and proprietary mRNA technology to address infectious diseases. The company focuses on building infrastructure for continuous vaccine development, ensuring timely access to effective immunizations in a rapidly changing global health landscape.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The global health landscape faces continuous threats from infectious diseases, requiring rapid development and deployment of effective vaccines. Traditional vaccine manufacturing processes can be slow and inflexible, hindering timely responses to emerging pandemics and regional outbreaks.
Solution
SK Bioscience develops and manufactures vaccines using advanced techniques, including proprietary mRNA technology, to address a range of infectious diseases. The company focuses on building robust infrastructure for continuous vaccine development, ensuring timely access to effective immunizations. SK Bioscience leverages its technology and manufacturing capabilities to develop novel vaccines and expand its global market presence through collaborations with global partners.
Target Audience
The primary target audience includes global healthcare organizations, governments, and pharmaceutical companies seeking reliable vaccine development and manufacturing partners.
Features
- Proprietary mRNA technology platform for rapid vaccine development
- Advanced vaccine manufacturing facilities with high production capacity
- Focus on developing vaccines for a range of infectious diseases
- Global partnerships for technology transfer and market expansion
- Pipeline of vaccine candidates, including mRNA-based vaccines